Metabolic Anomolies Associated With the 6 Month Clinical Evolution of Patients Suffering From Motor Conversion Disorder

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-01-29

Study Completion Date

2018-01-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of this study is to make a first evaluation of the relationship between metabolic abnormalities objectified by Positron emission tomography with 2-deoxy-2-\[fluorine-18\]fluoro- D-glucose integrated with computed tomography (PET CT 18 FDH) performed at rest at the onset of symptoms in patients with a first episode of motor conversion disorder and the persistence of a motor disability at 6 months measured by the modified Rankin score (mRS).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)

NCT00329706

Dementia

COMPLETED NA

Early Detection of Mild Cognitive Impairment in Individual Patients

NCT00243451

Mild Cognitive Impairment Mild Alzheimer's Disease

COMPLETED

Prediction of Dementia in Parkinson's Disease by Measuring Cerebral Metabolism With PET Scan

NCT02855021

Parkinson Disease

UNKNOWN NA

Isotopic Imaging for Prodromal Alzheimer's Disease

NCT01231295

Alzheimer Disease

COMPLETED

PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO)

NCT02062099

Memory Complaint Mild Cognitive Impairment Alzheimer Disease

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The secondary objectives of this study are:

A. To assess whether metabolic abnormalities objectified by PET CT 18 FDH performed at rest at the onset of symptoms may be predictive of persistent disability at 6 months as measured by the EDSS, the NIHSS and WHO status.

B. To assess whether metabolic abnormalities objectified by PET CT 18 FDH performed at rest at 3 months after diagnosis may be predictive of persistent motor disability at 6 months (EDSS, NIHSS, mRS, WHO) C. To search for and characterize any abnormalities of metabolism objectified in the initial PET CT 18 FDH predictive of persistent motor disability at 3 months.

D. To determine if there are persistent metabolic abnormalities 3 months post-diagnosis independently of the clinical course (marker trait).

E. Define the brain areas whose metabolism is often altered in patients with motor conversion disorders.

F. Establish a collection of biological samples from patients for future research studies of prognostic biomarkers of a motor conversion disorder.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Conversion Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study population

The study population consists of patients with paralysis, motor weakness or abnormal movements meeting DSM-IV criteria for motor conversion disorder consulting via the Emergency or Neurology department of participating centers.

Intervention: PET CT 18 FDG

PET CT 18 FDG

Intervention Type DEVICE

Positron emission tomography with 2-deoxy-2-\[fluorine-18\]fluoro- D-glucose integrated with computed tomography.

This intervention is required for the observational needs of the study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PET CT 18 FDG

Positron emission tomography with 2-deoxy-2-\[fluorine-18\]fluoro- D-glucose integrated with computed tomography.

This intervention is required for the observational needs of the study.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient must have given free and informed consent and signed the consent
* The patient must be affiliated with or beneficiary of a health insurance plan
* The patient meets DSM-IV criteria for motor conversion disorder (with paralysis, motor weakness or abnormal movements) lasting for less than 1 month and euthymic (HAMD score \< or = 7, as evaluated by a psychiatrist)
* First episode (incident cases)
* The latest symptom dates to within a month
* The patient is not under neuroleptics

Exclusion Criteria

* The subject is participating in another study
* The subject is in an exclusion period determined by a previous study
* The subject is under judicial protection, guardianship or curatorship
* The subject refuses to sign the consent
* It is not possible to correctly inform the patient
* The patient is pregnant, parturient or she is breastfeeding
* Specialized clinical neurological examination and brain and spinal cord MRI revealed an organic neurological cause
* The subject has a HAMD score \> 7
* The subject currently has manic/hypomanic episode, a diagnosis of substance abuse or dependency (excluding tobacco), a diagnosis of schizophrenia (any time in the past) or chronic neurological disease (active epilepsy, stroke, brain tumor)
* Suicidal or high risk for suicide (according to MINI assessment)
* Contra-indication for a PET scan
* Patient under neuroleptics at inclusion
* The last symptom happened over 1 month ago
* The patient has had previous episodes (prevalent cases)

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No